← Back to Search

Retinoid X Receptor Agonist

Bexarotene + Radiotherapy for Cutaneous T-Cell Lymphoma

Phase 1
Recruiting
Led By Sarah Noor, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥18 years
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Must not have
Patients unwilling to use two forms of barrier contraception while taking study medication
Concurrent diagnosis of systemic anaplastic large cell lymphoma (ALCL) or another non-Hodgkin lymphoma
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month post-treatment
Awards & highlights
No Placebo-Only Group

Summary

This trial tests the safety of combining bexarotene, a vitamin A derivative, with TSEB radiotherapy in patients with mycosis fungoides, a type of skin lymphoma. Bexarotene helps stop and kill cancer cells, while TSEB radiotherapy uses low-dose radiation to treat the skin. Researchers believe this combination may be more effective than using each treatment separately. Bexarotene has been used for both early and advanced cutaneous T-cell lymphoma (CTCL).

Who is the study for?
Adults with a skin lymphoma called mycosis fungoides (MF) can join this trial. They should be in relatively good health, able to consent, and have an ECOG performance status of 0-2. Participants must not be pregnant, use two forms of contraception if applicable, and cannot have had certain other treatments or conditions that would interfere with the study.
What is being tested?
The trial is testing the safety and effectiveness of combining bexarotene (a vitamin A-like drug) with TSEB radiotherapy—a type of radiation treatment for the skin—in treating MF. The goal is to see if using both treatments together works better than using them separately.
What are the potential side effects?
Potential side effects include those commonly associated with radiation therapy such as skin irritation or redness. Bexarotene may cause issues like headaches, rash, fatigue, nausea, blood lipid abnormalities and underactive thyroid.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I can take care of myself and am up and about more than half of the day.
Select...
My skin cancer is confirmed as mycosis fungoides by a biopsy.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am unwilling to use two forms of contraception during the study.
Select...
I have been diagnosed with ALCL or another type of non-Hodgkin lymphoma.
Select...
I do not have conditions like high blood fats that would make bexarotene unsafe for me.
Select...
I have been diagnosed with another type of cancer besides skin cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month post-treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month post-treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of radiation dermatitis grade 3+
Secondary study objectives
Overall skin response rate

Side effects data

From 2014 Phase 4 trial • 59 Patients • NCT01007448
57%
Hypertriglyceridemia
40%
Hypothyroidism
23%
Headache
23%
Hypercholesterolemia
17%
Skin exfoliation
13%
Bacterial test positive
13%
Thyroxine free decreased
10%
Blood triglycerides increased
10%
Alanine aminotransferase increased
10%
Urinary tract infection
10%
Aspartate aminotransferase increased
10%
Neutrophil count decreased
7%
Lethargy
7%
White blood cell count decreased
7%
Diarrhea
7%
Arthralgia
7%
Hypertension
7%
Nasopharyngitis
7%
Neutropenia
7%
Hypercreatinaemia
7%
Oedema peripheral
7%
Osteoporosis
7%
Proteinuria
7%
Fatigue
7%
Hypertriglyceridaemia
7%
Sinusitis
7%
Upper respiratory tract infection
3%
Atrioventricular block first degree
3%
Nausea
3%
Renal failure
3%
Cardiac failure congestive
3%
Hydronephrosis
3%
Peripheral vascular disorder
3%
Muscle spasms
3%
Syncope
3%
Cholecystitis
3%
Chest pain
3%
Bone marrow failure
3%
Lumbar vertebral fracture
100%
80%
60%
40%
20%
0%
Study treatment Arm
Bexarotene 150 mg/m^2/Day
Bexarotene 300 mg/m^2/Day

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Bexarotene Combined With RadiotherapyExperimental Treatment2 Interventions
Patients will be initiated on bexarotene 150 mg daily on Day 1, with dose increase to 300 mg daily on Day 15. Patients will receive Cycle 1 of TSEB on Day 22 (with 2 Gy given on two consecutive days -Day 22 and 23), with safety assessment on Day 52. Efficacy will first be assessed on Day 52 and then again on Day 82 by global response assessment, including mSWAT. Patients who have less than 70% reduction from baseline mSWAT score will be eligible for subsequent cycles of TSEB (administered as 4 Gy over 2 consecutive days), until mSWAT score reduction of ≥ 70%, and up to a total of 6 cycles. Treatment may continue until disease progression, unacceptable toxicity, recommended termination by treating physician, or termination of the study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bexarotene
2014
Completed Phase 4
~320

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Bexarotene, a form of vitamin A, activates retinoid X receptors, which can halt the growth of cancer cells and induce their death. TSEB Radiotherapy uses low-dose radiation to target and kill cancer cells on the skin's surface without penetrating deeper tissues. These mechanisms are crucial for CTCL patients as they offer targeted treatments that can effectively reduce tumor burden and manage symptoms with potentially fewer systemic side effects compared to more invasive therapies.

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,979 Previous Clinical Trials
599,818 Total Patients Enrolled
Sarah Noor, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
Brandon Imber, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
2 Previous Clinical Trials
39 Total Patients Enrolled

Media Library

Bexarotene (Retinoid X Receptor Agonist) Clinical Trial Eligibility Overview. Trial Name: NCT05296304 — Phase 1
Cutaneous T-Cell Lymphoma Research Study Groups: Bexarotene Combined With Radiotherapy
Cutaneous T-Cell Lymphoma Clinical Trial 2023: Bexarotene Highlights & Side Effects. Trial Name: NCT05296304 — Phase 1
Bexarotene (Retinoid X Receptor Agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05296304 — Phase 1
~1 spots leftby Mar 2025